Theralene

Quick links to important sections

Theralene

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Theralene

Property Description
Active ingredient Alimemazine (Trimeprazine)
Form Film-coated tablets, oral drops solution, syrup
Pharmacological class First-Generation Antihistamine
Common use Sedative, Antipruritic agent
Origin Synthetic organic compound

What Type of Medicine is Theralene (Alimemazine)?

Theralene is a prescription pharmaceutical product whose active ingredient is alimemazine, a substance also known by the non-proprietary name, trimeprazine. It is classified as a first-generation antihistamine that is chemically derived from the phenothiazine family, identifying it as a synthetic organic compound. The drug functions as a potent histamine H1 antagonist, competitively blocking the receptors responsible for many allergic responses in the body. The compound is typically prepared as a stable salt, such as alimemazine hemitartrate or trimeprazine tartrate.


What is Theralene's General Purpose and Function?

The general purpose of Theralene is derived from its dual pharmacological action: suppressing allergic reactions and providing significant Central Nervous System (CNS) depression. Pharmacological studies have clinically recognized this agent for its ability to affect CNS activity, a feature distinguishing it from newer antihistamines. This physiological action means the medicine is utilized as an effective anti-allergic agent and antipruritic agent for the relief of generalized itching. Furthermore, its ability to easily cross the blood-brain barrier establishes its classification as a potent sedative-hypnotic agent, promoting a general calming effect. Its chemical structure also confers ancillary anticholinergic and antiserotonin properties, which further contribute to its functional profile, for instance, in providing night-time relief from allergic symptoms that disrupt sleep.


What Forms and Preparations are Available?

Theralene is supplied as a single active ingredient product in multiple pharmaceutical preparations intended for the oral route of administration. These forms ensure flexible administration across different patient groups, including film-coated tablets for solid-dose needs and a syrup or oral drops solution for patients, such as children, who require precise liquid dosing or have difficulty swallowing tablets. The availability of liquid forms is a key differentiating factor for its use in pediatric medicine.

Regulatory References

  1. NIH StatPearls on Trimeprazine

What side effects are possible with Theralene?

Possible Side Effects and Safety Information

Theralene (alimemazine tartrate) is associated with adverse reactions primarily related to its effects on the central and autonomic nervous systems. All factual statements are based on regulatory documentation for the drug.

Commonly Documented Adverse Reactions

System-Organ Class Common Side Effects (Frequency ge 1/100)
Nervous System Drowsiness, Acute dystonias or dyskinesias (especially in children/young adults), Parkinsonism (in adults/elderly)
Gastrointestinal Dry mouth, Constipation
Respiratory Nasal congestion

Serious and Clinically Significant Adverse Reactions

Rare but serious reactions have been reported, including Neuroleptic Malignant Syndrome (NMS), which is characterized by high fever, muscle rigidity, and altered mental status. Other clinically significant risks include Cardiac Arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation), Agranulocytosis (a severe blood disorder), and obstructive-type Jaundice (liver toxicity).

Population-Specific Safety Considerations

  • Children: The drug is contraindicated for use in children under 2 years old due to the risk of marked sedation and respiratory depression. Acute dystonias are more common in children and young adults.
  • Elderly: This population is particularly susceptible to postural hypotension (dizziness upon standing), extrapyramidal effects (Parkinsonism), and may experience increased sedation or confusion.

Safety Restrictions and Limitations

Use is contraindicated in patients with known hypersensitivity to phenothiazines, severe hepatic or renal dysfunction, Parkinson's disease, epilepsy, myasthenia gravis, or a history of narrow-angle glaucoma or agranulocytosis. Patients should be warned about drowsiness during the initial phase of treatment and advised not to drive or operate machinery. Concomitant use with alcohol is strongly advised against as it may significantly increase the risk of central nervous system depression and serious breathing difficulties.

Overdose and Emergency Response

Overdose and When to Seek Help

Theralene (alimemazine) overdose can lead to serious, potentially life-threatening symptoms, primarily affecting the central nervous system (CNS) and motor control. It is critical to recognize that any suspected or known overdose requires immediate professional medical attention.


Documented Overdose Manifestations

Official regulatory information describes a range of severe symptoms resulting from overdose, which are consistent with the drug's classification as a phenothiazine derivative. These manifestations include:

  • Central Nervous System Effects: Severe drowsiness, seizures, restlessness, insomnia, flushing or redness of the face, and hallucinations.
  • Motor/Neuromuscular Effects: Clumsiness or unsteadiness, trembling and shaking of the hands, muscle spasms (especially of the neck and back), shuffling walk, and tic-like (jerky) movements of the head and face.

Required Emergency Action

Immediate medical help must be sought if any of the severe symptoms of overdose, such as seizures, severe drowsiness, hallucinations, or muscle spasms, occur. Treatment of overdose, often based on the phenothiazine class, may involve specific procedural instructions. For instance, authorized texts may explicitly state Do NOT induce vomiting in the case of a phenothiazine overdose. Emergency response is symptomatic and supportive, focused on managing the severe CNS and motor toxicity presented.

Therapeutic Uses of Theralene

What Theralene Treats: Main Uses and Benefits

Alimemazine (trimeprazine) is commonly used in clinical settings that involve acute or unstable symptom patterns, offering symptomatic relief across therapeutic domains where distressing symptoms interfere with daily functioning. The primary therapeutic uses are associated with symptomatic relief across key domains, including the management of certain physical symptoms and tension.

The medication is commonly used to help with symptom clusters related to heightened physiological activity, including intense allergic pruritus, acute sleep disturbance, generalized anxiety, and pre-operative sedation. It is generally considered relevant in conditions characterized by periods of heightened symptoms, such as recurrent or episodic manifestations where symptoms create noticeable physiological strain.

“The medication supports patients during difficult episodes by easing distress and is commonly used for short-term symptomatic assistance when symptoms become temporarily overwhelming.”

This supportive role provides support that helps ease the overall symptom burden, contributes to improved comfort during periods of heightened symptoms, and may assist with maintaining functional stability in relevant clinical contexts.


Quick Fact: Symptomatic Support for Itching and Tension
Alimemazine is commonly used to help with managing symptoms related to physical discomfort such as severe allergic itching, and may assist with the emotional tension that often accompanies hyperarousal.

Eligibility and Restrictions for Use

Who Can and Cannot Use Theralene? (Alimemazine)

Official regulatory documents define strict criteria for the use of alimemazine, listing specific populations who are contraindicated and others who require special caution.


Contraindicated Populations (Must Not Use)

The medicine is absolutely contraindicated for patients with known hypersensitivity to alimemazine, other phenothiazines, or any of the product's excipients. Other populations who must not use this medicine include those with:

  • Children less than 2 or 3 years of age, with the precise age limit depending on the specific product formulation, due to the risk of marked sedation and respiratory depression.
  • Hepatic or renal dysfunction.
  • Epilepsy, Parkinson’s disease, Hypothyroidism, Phaeochromocytoma, or Myasthenia gravis.
  • A history of narrow angle glaucoma, agranulocytosis, or prostatic hypertrophy.

Restricted or Cautionary Use

Use is not recommended for pregnant women (unless considered essential by a physician) or women who are breast-feeding, as phenothiazines may be excreted in human milk, requiring discontinuation of breast-feeding during treatment. Elderly patients and individuals with certain cardiovascular diseases require special caution due to increased susceptibility to effects like orthostatic hypotension and arrhythmias. Caution is also necessary for patients with a history of seizures.

What should I know about interactions with other medicines?

The official regulatory profile for Theralene (Alimemazine) interactions is structured around its primary pharmacological effects, categorized into Additive Pharmacodynamic Effects and Altered Pharmacokinetic Exposure.

Formal Restrictions and Contraindications

Co-administration with Alcohol and alcohol-containing medicines is strictly advised against and contraindicated in acute intoxication due to the risk of potentiating Central Nervous System (CNS) depression. Adrenaline (Epinephrine) is prohibited for use in overdose management, as it may worsen circulatory collapse. The label also specifies that Alimemazine is contraindicated in children less than 2 years of age because of the heightened risk of marked sedation and respiratory depression.

Documented Interaction Patterns

Pharmacodynamic Interactions: Alimemazine may cause additive sedative effects when taken with other CNS depressants, including opiates, barbiturates, or anxiolytics. Combining it with Anticholinergic Drugs (such as tricyclic antidepressants or MAOIs) may result in exaggerated antimuscarinic effects. An exaggerated hypotensive effect is also documented when co-administered with antihypertensive drugs. Caution is noted for combination with QT-prolonging drugs.

Pharmacokinetic Interactions and Timing: The regulatory profile notes that Antacids, Topical Gastrointestinal Tract Drugs, and Adsorbents can reduce the absorption of Alimemazine. To mitigate this decreased exposure, these products should be administered with a timing separation of more than two hours, if possible. Changes in the plasma concentrations of Propranolol and Phenobarbital have been observed, but are categorized as not of clinical significance. Elderly patients are officially noted as being more susceptible to orthostatic hypotension and severe anticholinergic effects.

Mechanism of Action

How Theralene Works

The mechanism of action for Alimemazine is defined by its ability to engage multiple central and peripheral biological targets, leading to distinct physiological modulations.

Central Blockade of Arousal Pathways

Alimemazine acts as a competitive antagonist or inverse agonist at the Histamine H1 receptors ( HRH1) throughout the Central Nervous System (CNS). Due to its high lipophilicity, the molecule rapidly crosses the blood-brain barrier and modulates the activity of the histaminergic arousal system—the neural pathway critical for maintaining wakefulness. This action is accompanied by ancillary antagonism at central Muscarinic Acetylcholine and specific Serotonin receptors. This concerted central modulation results in a reduction in central histaminergic drive, influencing the physiological state of alertness.

Peripheral Modulation and Constraints

Outside the CNS, the mechanism involves blocking the HRH1 receptors on peripheral sensory nerve endings and vascular tissue. This interrupts the signaling sequence originating from histamine-dependent signaling. This mechanistic domain modifies the physiological consequences of excessive histamine activity, such as microvascular leakage and local fluid extravasation. The drug’s action is defined by a reversible, competitive interaction, which makes the mechanism highly concentration-dependent and subject to functional constraints when faced with pathologically high levels of endogenous mediator.

Dosage and Administration Information

Theralene (alimemazine) is administered exclusively via the oral route, consistent with the official product labeling across regions. The medicine is supplied as film-coated tablets, syrup, and concentrated oral drops solution, which facilitates precise and flexible administration.


Standard Administration and Dosing

The medicine is used according to specific, documented schedules. For ongoing symptom management, such as pruritus, the total daily dose is typically divided for administration two or three times per day. A larger portion of the daily dose is frequently taken in the evening to align with the desired timing profile. The standard adult dosing regimen for pruritus is 10 mg two or three times daily, with an allowance for up to 100 mg per day in specific intractable cases. For short-term sleep disturbance, a single dose between 10 mg and 30 mg is administered one to two hours before bedtime.

The overarching principle for all use is the administration of the lowest effective dose for the shortest possible treatment time.


Specific Procedural Guidelines

Usage Context Official Procedural Instruction
Older Adults (Elderly) The dose for older adults requires reduction; for pruritus, this is often 10 mg once or twice daily.
Pediatric Population Use is not recommended for patients under 2 years of age. Specific divided regimens apply to older children.
Liquid Form Preparation Oral drops solution must be diluted with a non-milk drink before ingestion. All liquid forms require measuring with a graduated device for accuracy.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Theralene


Evidence for Use in Symptomatic Relief of Pruritus (Itching)

The use of alimemazine (trimeprazine) was studied to explore symptom patterns in patients experiencing itching, particularly that associated with acute or disruptive episodes linked to allergic skin conditions. The research available includes trials from prior decades, such as short-term Randomized Controlled Trials (RCTs) and general clinical studies. These trials research examined metrics such as the duration and intensity of itching, alongside patient-reported outcomes describing perceived discomfort. These studies were relevant in trials assessing short-term or episodic symptom patterns in both adults and children (aged 2 years and older).

The findings describe patterns observed in the studies where measurements of itch severity were taken and documented over the observation period. Evidence is part of the broader research landscape for first-generation antihistamines. However, the evidence is limited by the age and size of the primary trials. Comparative evidence is limited regarding its evaluation alongside newer, non-sedating antihistamines. Long-term outcomes are not fully established for patients with chronic, sustained pruritus.


Evidence for Use in Acute Sleep Disturbance

The medicine was evaluated in research exploring outcomes related to acute sleep problems such as difficulty falling asleep or persistent night waking. Small, short-term Randomized Controlled Trials and systematic reviews studies monitored metrics like the time taken to fall asleep and the frequency of night waking. Research in this area included both adults and, specifically, young children (e.g., aged 1 to 5 years) experiencing acute sleep disturbance.

Research reports documented changes measured during the study period, which were often based on patient-reported outcomes. The certainty regarding these findings remains low. Sample sizes were modest in many of the primary trials, and the follow-up durations were limited.


What Remains Uncertain and Research Gaps

Research exploring long-term effects are not fully established for alimemazine across any of its studied indications. Most available studies focused on research exploring short-term symptom changes over periods lasting from a few days to a few weeks. Studies provide insight into symptom patterns for acute use, but there is a lack of systematic data regarding sustained or chronic administration. Furthermore, the data for certain groups remain insufficient, particularly for older adults or pregnant individuals.

Key Studies & References

  1. Public Assessment Report for Alimemazine tartrate 10 mg film-coated tablets (HPRA)
  2. Systematic review of pharmacological treatments for settling problems and night waking in young children

Frequently Asked Questions (FAQ)

Common questions about Theralene (FAQ)


Q: How quickly can I expect Theralene to start working?

Official product information suggests a timeframe for action when used for acute sleep disturbance. For this purpose, regulatory documents indicate a dose is typically administered one to two hours before bedtime. This timing is aligned with the expected onset of the medicine's sedative effect.


Q: Can Theralene be taken with common pain relievers like ibuprofen?

Regulatory documentation does not specifically list common pain relievers like ibuprofen (a nonsteroidal anti-inflammatory drug) as a known interaction. However, the official label notes the potential for enhanced central nervous system (CNS) depression when taken alongside other CNS-depressing medicines. Information regarding the use of multiple medications should be reviewed by a healthcare professional.


Q: What is the difference between Theralene and similar-sounding medicines?

Theralene is officially classified as a first-generation antihistamine that belongs to the phenothiazine family of drugs. This chemical classification helps define its functional profile as both a sedative agent and an anti-allergic agent, distinguishing it from newer antihistamines or other drug classes.


Q: What is the typical duration of treatment with Theralene?

According to the official guidance, the fundamental principle for using Theralene is the administration of the lowest effective dose for the shortest possible treatment time. This approach supports its use for short-term or acute symptom management rather than chronic, sustained administration.


Q: What happens if I miss a dose of Theralene?

Patient information typically describes the guidance to be followed for a forgotten dose, which often involves taking it when remembered. However, official documentation specifies that compensating for a missed dose by taking a double dose is generally not advised.


Q: Is Theralene safe to use while breastfeeding?

Regulatory documents state that use while breast-feeding is generally advised against. Official information indicates that phenothiazines, the class of drug Theralene belongs to, may be excreted into human milk, which may require discontinuation of breast-feeding during treatment.


Q: What is meant by the official warning about 'paradoxical reactions' with Theralene?

The official documentation advises monitoring for possible paradoxical reactions, especially in children. These reactions are described as effects that are the opposite of the intended outcome, and may include symptoms such as restlessness, agitation, or excitability instead of the expected calming effect.


Q: Why do official documents mention 'long-term safety' for Theralene?

The focus on long-term safety reflects regulatory constraints and research limitations. Since most available studies focus on short-term symptom changes, the limited long-term data explains why official documents maintain a focus on monitoring and short-term use.


Q: Is it true that Theralene is sometimes used for things like severe itching?

Yes, official indications for Theralene, as described in regulatory documents, include the symptomatic relief of generalized pruritus (itching). It is also officially indicated for conditions such as urticaria (hives/itchy rash).


Q: How does the use of Theralene relate to kidney function?

Regulatory documents list severe hepatic (liver) or renal (kidney) dysfunction as a contraindication for using Theralene. This is because normal kidney function is important for the body to properly clear the drug from the system, and impairment can lead to accumulation.


Q: What information is available about the effect of Theralene during pregnancy?

Official guidance indicates that use during pregnancy is advised against. Any use during this period requires specialized review due to insufficient clinical data regarding specific risks across the different stages of pregnancy.


Q: Does Theralene change the way other prescription medications are processed by the body?

Yes, the regulatory profile notes interactions that can alter the way some medicines are handled. Specifically, products like antacids or adsorbents can reduce the absorption of Theralene. Official guidance describes a timing separation of more than two hours to help mitigate this effect.


Q: Is the 'how Theralene works' mechanism similar to other classes of drugs?

Theralene's primary mechanism involves the antagonism (blocking) of histamine H1 receptors in the body. This specific action is a fundamental function that is shared by all medicines classified as first-generation antihistamines.


Q: Do people who take Theralene report changes in their mood or energy levels?

Regulatory documents list a range of potential adverse reactions, including psychiatric disorders such as agitation or insomnia. Furthermore, the drug's core action as a central nervous system depressant may influence overall feelings of energy and alertness.

How should Theralene be stored and disposed of?

How to Store and Dispose of Theralene

Theralene must be stored according to specific regulatory guidelines to maintain its stability and ensure safety. For the medicinal product as packaged for sale, it is typically required to store it below 30 C in the original container and keep the container tightly closed to protect it from moisture.

Crucially, this and all medicines must be stored out of the sight and reach of children to prevent accidental exposure.

Specific in-use stability periods apply when the product is incorporated into animal feed, with shelf-lives ranging from two weeks up to two months depending on the formulation and feed type.

When disposing of any unused Theralene or waste material, it is important to follow the labeled instructions, which mandate disposal in accordance with local requirements to ensure environmental safety and adherence to proper procedures.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Theralene found in:

A-Z Index: